To further demonstrate the utility of the PLK1 NanoBRET assay, we profiled adavosertib (MK-1775/AZD1775), a WEE1 kinase inhibitor in clinical development for the treatment of pancreatic cancer, whose kinase selectivity has been the subject of debate in the literature [13,22,23]. Here, WEE1 is linked to familial pancreatic carcinoma.